Delving into the Latest Updates on Dianthus Therapeutics OpCo, Inc. with Synapse

概览

疾病领域	数量

神经系统疾病	1
肿瘤	1
免疫系统疾病	1

排名前五的药物类型	数量

单克隆抗体	1

排名前五的靶点	数量

C1S(补体C1s)	1

关联

1

项与 Dianthus Therapeutics OpCo, Inc. 相关的药物

DNTH-103

靶点

C1S

作用机制

C1S抑制剂

在研机构

Dianthus Therapeutics OpCo, Inc.初创企业 [+3]

原研机构

Dianthus Therapeutics OpCo, Inc.初创企业

在研适应症

慢性炎症性脱髓鞘性多发性神经病 [+3]

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

3

项与 Dianthus Therapeutics OpCo, Inc. 相关的临床试验

NCT06858579

/ Recruiting临床3期

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).

开始日期2025-02-10

申办/合作机构

Dianthus Therapeutics OpCo, Inc.初创企业

NCT06537999

/ Recruiting临床2期

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults with Multifocal Motor Neuropathy (MOMENTUM)

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with multifocal motor neuropathy (MMN).

开始日期2024-09-17

申办/合作机构

Dianthus Therapeutics OpCo, Inc.初创企业

NCT06282159

/ Recruiting临床2期

A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).

开始日期2024-02-23

申办/合作机构

Dianthus Therapeutics OpCo, Inc.初创企业

100 项与 Dianthus Therapeutics OpCo, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Dianthus Therapeutics OpCo, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Dianthus Therapeutics OpCo, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Dianthus Therapeutics OpCo, Inc. 相关的转化医学

登录后查看更多信息